Traditional medicine is used in 170 WHO Member States, yet it receives less than 1% of global health research funding. That mismatch sums up a major challenge for Ayurveda. People already rely on it. What needs to catch up is the depth of evidence behind the products they buy.
Change is already under way. Across India’s Ayurveda industry, research is moving closer to the product itself. Brands are putting money into better ways of identifying herbs, keeping formulations consistent, and testing what happens when people actually use them. Clinical trials are easier to find, lab reports are starting to reach consumers, and even classical formulations are being studied with contemporary methods.
This is not Ayurveda giving up its roots for modern science. It is traditional knowledge being asked to show its working.
Good research starts before the trial
A published study is the most visible kind of evidence. But by the time a formulation reaches a clinical trial, a lot of scientific groundwork should already be done.
Plants vary naturally. Ashwagandha grown in one region may have a different chemical profile from the same crop grown elsewhere, and harvesting conditions can change the raw material too. If that variation is not understood, two batches sold under the same ingredient name may not be identical.
That is why standardisation matters so much. The Central Council for Research in Ayurvedic Sciences (CCRAS) develops pharmacopoeial standards and reference markers to help identify and standardise Ayurvedic ingredients. It also prepares standard operating procedures for formulations and does quality-control work before products enter pre-clinical or clinical research.
For brands, the logic is simple. Before asking whether a formulation works, you need to be confident that today’s batch matches tomorrow’s.
R&D is moving to the start of the process
This has changed how companies approach research. Instead of treating it as something that happens once a product already exists, brands are bringing scientists into formulation work much earlier.
Kapiva is one example. It runs a 25,000 sq. ft. R&D centre in Bengaluru with over 30 researchers and scientists, and its in-house programme runs from the chemistry of individual ingredients through formulation development to clinical research.
The company has also looked beyond its own pipeline. In 2026 it launched the Kapiva Innovation Fund, a pool of up to ₹50 crore for researchers, institutions and startups working on scientific innovation in Ayurveda. The fund is meant to back projects that need research infrastructure and a route from early idea to validation.
This matters because one of Ayurveda’s constraints is structural. Good research needs laboratories, expertise and funding long before there is anything to sell. Kapiva’s approach shows a wider shift in the sector, where R&D is treated as infrastructure and not just a marketing line.
The pattern appears among established players too. Himalaya Wellness runs a Bengaluru R&D centre of more than 130,000 sq. ft. with over 200 physicians and scientists, while Dabur operates an 80,000 sq. ft. facility in Ghaziabad with more than 100 scientists and botanists. Their methods differ, but both show research and standardisation becoming central to product development and not something bolted on at the communication stage.
The next step: testing the finished formulation
Research on a single herb can reveal a lot, but it cannot automatically predict what a finished multi-herb product will do. That gap is pushing more brands to study the exact formulation they sell.
Kapiva’s Shilajit Gold is a recent example. The finished formulation was assessed in an eight-week, randomised, placebo-controlled clinical trial in healthy men, looking at physical-performance outcomes and testosterone. Researchers affiliated with Kapiva have since published a review of the possible mechanisms by which the Shilajit Gold herbal complex might influence athletic performance.
That disclosure of affiliation matters as much as the results. Credible research does not pretend commercial involvement is absent. It makes that involvement visible so readers can weigh the evidence in context.
More studies do not automatically mean better evidence
This is where the next phase of credibility gets harder. “Clinically studied” is useful, but it must not turn into another way of saying “scientifically proven” on a label.
Study design matters. A randomised controlled trial answers different questions from an observational study. A study with 30 participants offers a different level of confidence from one with several hundred. And results compared with a participant’s own starting point are not the same as showing a meaningful difference against placebo.
CCRAS acknowledges this range. Its clinical research programme uses methods from observational studies and pilot trials to randomised controlled trials and systematic reviews, depending on the question.
The stronger brands will be the ones that explain what a study shows and what it does not.
Openness may matter as much as the research
Scientific credibility is hard to build behind closed doors. If a product has been tested, consumers should be able to see meaningful detail about it. If the company funded a study, that should be stated. If the research is preliminary, the product’s language should say so.
This is already part of the global conversation. The WHO Global Traditional Medicine Strategy 2025–2034 puts stronger evidence and suitable regulation at the centre of integrating traditional medicine into health systems. The second WHO Global Summit on Traditional Medicine went further, calling for more research investment while noting that traditional medicine gets under 1% of global health research funding. For India’s Ayurvedic industry, that brings both pressure and opportunity.
The most credible brands welcome questions
For decades, Ayurveda brands could lean heavily on familiarity. Consumers knew the herbs, the tradition and often the company.
That trust still counts, but a new layer is being added. People can now ask where an ingredient came from and how a formulation was standardised. They can look for an actual clinical study and not just accept “clinically tested”. They can ask who paid for it and whether its limitations are acknowledged.
Kapiva is building its own research infrastructure. Established companies such as Himalaya and Dabur have substantial scientific capabilities. Government research bodies are widening formal standards and clinical-research frameworks, and WHO is taking the same conversation to a global stage.
The outcome is a healthier idea of what modern Ayurveda can be: not Ayurveda dressed up to look scientific, but Ayurveda that is increasingly willing to be measured, tested and questioned.






